Capelle Aan Den Ijssel

Researchers are collecting real-world data to evaluate the effectiveness and safety of new systemic treatments such as biologics and Janus kinase inhibitors in patients with atopic dermatitis. The BioDay Registry also studies the impact of these treatments on related allergic conditions like food allergies, asthma, and conjunctivitis. This observational registry gathers information from multiple centers to better understand treatment outcomes in daily clinical practice. Participants include both adults and children receiving new systemic therapies for their atopic dermatitis. There is no assigned treatment in the study since it is observational instead, data is collected as patients receive their prescribed medications. The registry includes modules for atopic comorbidities and monitors patients over time to capture the effects of treatment in routine care. Participants will provide data through questionnaires and clinical assessments at multiple timepoints, including baseline, 16 weeks, 1 year, 2 years, and annually up to 5 years. Researchers track changes in disease symptoms, side effects, drug continuation rates, laboratory results, comorbid conditions, and any dose adjustments. This long-term follow-up aims to improve understanding of treatment safety and effectiveness in everyday settings.

Researchers are exploring ways to preserve the rectum in patients with rectal cancer who show a good clinical response after neoadjuvant chemoradiation. This phase II feasibility study compares two local treatment approaches contact x-ray brachytherapy versus extending the waiting period with or without local excision. The goal is to determine how often organ preservation can be achieved and to optimize treatment strategies for patients with a near-complete response or small residual tumor. The study includes two experimental groups. In one group, contact x-ray brachytherapy is delivered as three 30 Gy fractions to the tumor within 14 weeks after completing chemoradiation, with two-week intervals between doses. Patients are monitored every three months afterward. The other group extends the waiting interval by 6 to 8 weeks after the initial response evaluation, with additional assessments to check for tumor response. Patients showing complete response enter a watch-and-wait approach, while those with small remaining lesions may receive local excision, followed by risk-based recommendations for further treatment. Participants undergo regular clinical, radiological, and endoscopic assessments to monitor tumor response and detect any disease progression. The primary outcome is the rate of successful organ preservation one year after randomization. Secondary outcomes include treatment-related toxicity, postoperative complications, bowel and bladder function, quality of life, tumor regrowth, disease-free survival, and overall survival measured up to five years. An intensive follow-up program supports early detection of recurrence and timely surgical intervention if needed.

This research aims to develop and evaluate a personalized, patient-centered follow-up program for people who have had surgery to treat colorectal carcinoma without metastasis. The study focuses on improving quality of life and reducing stress by moving much of the follow-up care from hospital visits to the patients home. The program will be compared to standard follow-up care over 36 months to see if it maintains quality of life while decreasing the number of hospital appointments. The study involves home-based monitoring that includes regular blood tests to check carcinoembryonic antigen CEA levels using an automatic capillary blood withdrawal device every six months for the first two years and annually thereafter. Vital signs are measured quarterly during the first two years and every six months after that using a remote monitoring system. Quality of life is assessed through questionnaires at the same intervals. One in-hospital medical imaging exam is scheduled one year after surgery according to national guidelines. The follow-up is aligned with Dutch national recommendations and adapts to any updates. Participants will take part for 36 months, during which their quality of life and number of hospital visits will be monitored. Researchers will collect blood samples, vital signs, and questionnaire responses remotely from home, with one hospital imaging visit after one year. The primary outcomes measured are health-related quality of life using the EQ 5D-5L questionnaire and the count of in-hospital appointments. This approach aims to provide a fuller picture of patients health while reducing hospital stress and visits.

Researchers are investigating how various factors beyond tumor stage, such as biochemical, histopathological, genomic, environmental, and clinical characteristics, affect the outcomes of patients diagnosed with colorectal cancer CRC, small bowel cancer, and anal cancer. This observational study aims to collect detailed information from diagnosis through long-term follow-up to better understand prognosis and treatment effects in both early and late-stage cancers. The study addresses the gap between clinical trial populations and real-world patients by including a broader patient group treated in general practice. Participants will be followed prospectively from their initial diagnosis until death. Data collection includes medical history, clinical parameters, imaging, pathology, tumor details, treatments, hospital stays, interventions, and adverse events. With separate consent, patient-reported quality of life and work ability information will also be gathered. Additionally, biological samples obtained during routine care may be collected for further observational and molecular research. This cohort serves as a platform for evaluating new interventions through a Trials within Cohorts TwiCs design. Throughout up to ten years of follow-up, participants will undergo assessments of progression-free survival, disease-free survival, overall survival, and serious adverse events. Quality of life and work ability are assessed at intervals of 3, 6, 12, 24, 36, and 48 months. This extensive data collection supports a wide range of research aims including prognostic studies, molecular analyses, comparisons of new treatments, and health policy evaluations. The study provides a comprehensive view of treatment outcomes and patient experiences in everyday clinical settings.